Background
Imagine a person with chronic pain entering his or her pharmacy with a prescription for "oxycodone ER, 40 mg PO BID. " Most pharmacists have encountered this prescription many times. One out of every 5 people in Canada experiences chronic pain, 1 and many use opioids as part of managing this. Pharmacists play a key role in promoting rational opioid use, balancing safety with decreased pain and overall quality of life. This "opioid stewardship" by pharmacists is especially important in the context of the current opioid crisis. 7 In 2017, 2987 Canadians died from apparent opioid overdoses, 2 and there were, on average, 16
Canadians hospitalized each day for opioid poisoning. 3 In Ontario, one-third of opioid-related deaths and one-half of opioid-related hospitalizations were among people with an active opioid prescription. 4, 5 There is a clear relationship between prescribed opioid dose and overdose death in patients with chronic pain. 6 With heightened awareness of the deadly opioid crisis, people with chronic pain who are using opioids are at risk of being stigmatized. They are often confused and concerned about decisions regarding their opioid use as new evidence emerges about risk. The Canadian Guideline for Opioids for Chronic Non-Cancer Pain, hereafter referred to as the Guideline, was published in May 2017 to address the use of opioids to manage chronic pain in adults. 1 The full Guideline is available through MAGICApp online: https://www .magicapp.org/app#/guideline/1855, a unique platform that provides recommendations and evidence summaries in a multilayer format, enabling efficient access to the most relevant information for clinical decisions. MAGICApp also allows for ongoing updates as new evidence emerges. The Guideline can also be accessed through the National Pain Centre based at McMaster University (http://nationalpaincentre .mcmaster.ca/guidelines.html). Pharmacists see patients up to 10 times more frequently than primary care physicians for the management of chronic diseases 8 and are thus well positioned to provide important assessment and opioid therapy management. This ongoing therapeutic relationship creates an opportunity to inform people and help them make rational decisions about their opioids. It also creates opportunities to identify patterns of risky medication use over time, which may not become apparent during brief encounters with their prescriber. Even if pharmacists are aware of the Guideline, many find it overwhelming to navigate and implement in their practice. The terminology that is used is nuanced and it is difficult to interpret without understanding the methodology of guideline development. For example, recommendations are classified as strong or weak. This may lead pharmacists and patients to ask why care should be dictated by a weak recommendation. People using opioids for chronic pain may resist changes recommended by the Guideline. Concepts such as a threshold dose, or the need to trial a taper of opioids, need to be communicated with a motivational approach and as part PRaCtiCe guideLiNes of individualized care planning. Considering what is important to the person will help him or her buy into the recommendations and ultimately improve the success of any intervention.
Putting all of this together in a busy practice can be daunting. This article aims to provide important background on the Guideline and proposes a framework to help pharmacists implement the Guideline's recommendations in practice and inform patient care.
Guideline development
The guideline development team, clinical experts, patient advisors and the National Opioid Use Guideline Group identified research questions about the use of opioids for chronic pain. Following the release of the Guideline, there was some controversy regarding perceived conflicts of interest of people involved with development. The Canadian Institute for Health Research (CIHR) investigated and concluded that the process for development of the Guideline was scientifically rigorous and that the Guideline provides unbiased, evidence-based guidance to clinicians that is aligned with international comparators. 9 The guideline development team performed systematic reviews for each question to identify evidence and assess its quality. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) system was applied to move evidence to recommendations. This system grades the quality or certainty of evidence and, considering patient values and preferences, the strength of the recommendation (strong or weak). Table 1 outlines the implications of strong and weak recommendations for clinicians and patients. For example, the recommendation to restrict dosing to less than 90 mg morphine equivalent dose (MED) daily for patients starting opioid therapy is classified as strong. This means for clinicians that (almost) everyone starting opioids should stay below this threshold.
Evidence (randomized controlled trials or observational studies) was only identified to move 10 of the systematic review questions to recommendations. If there wasn't enough evidence identified, Best Practice statements were created if they were supported by indirect evidence and associated with large benefit, while Expert Guidance statements provide direction in areas with little or no published evidence.
What recommendations are included in the Guideline?
The Guideline included 10 evidence-based recommendations related to initiation of opioid therapy, opioid dosing and opioid rotation and tapering. These are outlined in Box 1. Three best practice statements were included, informed by indirect evidence (Box 2). Ten expert guidance statements were included in the Guideline, to address areas where evidence was very limited or absent. As evidence emerges, clinical practice recommendations may be warranted 
Framework for pharmacists to apply the Guideline in practice
As opioid stewards, pharmacists must assess all patients initiating opioid therapy and provide ongoing monitoring of effectiveness (pain and function), safety (dose, adverse effects, longterm consequences of opioids, aberrant behaviours) and adherence as part of their care plan. This assessment and monitoring forms the foundation for application of the Guideline to individuals with chronic pain. Recognizing the challenges that pharmacists face in daily practice, we propose a framework ( Table 2 ) that identifies opportunities to implement the Guideline in practice. These include gathering appropriate information, assessing, Table 1 .
bOX 2 Best practice statements
Informed consent: Acquire informed consent through a discussion of potential benefits, adverse effects and complications to facilitate shared-care decision making on whether to proceed with opioid therapy.
Monitoring:
Clinicians should monitor patients using opioid therapy for their response to treatment.
Contraindications:
Clinicians should address any potential contraindications and exchange relevant information with the patient's general practitioner and/or pharmacists.
PRaCtiCe guideLiNes expert guidance statements
What is the pharmacist role?
Restriction in amounts of opioid prescribed
Professional regulatory bodies have set limits using different restrictions in amounts of opioids.
Be aware of restrictions on amount of opioids prescribed in your province. Use clinical judgement to assess quantities when dispensing. Consult with prescribers and provide direction on appropriate quantities. Dispense part-fills of prescriptions to limit quantity dispensed at one time.
Be prepared to discuss the risks related to opioids to justify the restriction. Share how reduced quantities may protect patients from loss or theft.
Immediate vs. controlled release opioids ER formulations are appropriate for patients with continuous pain. Activity-related pain may not require ER treatment, and IR alone may be selected.
Recommend ER formulations for patients with continuous pain, IR formulations for activity-related pain, or pain that flares for short periods. Other considerations when selecting ER vs IR products: convenience (number of daily administration times), potential reinforcing effect of "pill popping" to reduce pain, pharmacokinetics (shorter time to peak with IR products may lead to rewarding effects) (i.e., subtle euphoric effects).
Coprescribing with opioids
Benzodiazepines and opioid should not be prescribed together.
Discuss starting a benzodiazepine taper with the patient before he or she starts on opioids. Create a benzodiazepine tapering plan in collaboration with patient and prescriber. It may be unrealistic to complete the benzodiazepine taper prior to initiating opioid therapy. Review history related to indication for the benzodiazepine (e.g., anxiety, sleep), and select an alternative therapy to initiate or recommend if appropriate.
Sleep apnea (opioid induced)
Reduce opioid dose and/or provide treatment for sleep apnea without reducing dose.
Ask patients about their sleep. Recommend a sleep study for patients on high doses of opioids. Explore the risk/benefit of opioids with patients in the context of a sleep apnea diagnosis. Use a motivational approach to help patients taper.
Hypogonadism (opioid induced)
Evaluate for hypogonadism and offer opioid tapering as the initial strategy to correct. May offer testosterone supplementation therapy second.
Ask about sexual function, amenorrhea, fatigue, mood changes. Discuss with patients the link between these symptoms of hypogonadism and opioid use. Use a motivational approach to help patients taper.
Urine drug screening
Perform at baseline and on an annual basis, more frequently if elevated risk or aberrant behaviours.
Recommend urine drug screening by prescribers and support the interpretation of results (e.g., detection cutoff values, metabolites). Point-of-care tests may be performed in the pharmacy.
Treatment agreements
A written treatment agreement may be useful.
Pharmacists may complete treatment agreements in collaboration with the prescriber and patients. Ask about treatment agreements in place, and request they be shared to promote collaboration and structure expectations.
Tamperresistant formulations
May be used to reduce risks of altering intended delivery system (i.e., crushing and injecting oral formulation), but do not reduce most common mode of misuse (oral ingestion).
Be aware of the availability and limitations of tamper-resistant formulations (e.g., OxyNeo®). Continue to monitor for aberrant behaviours when tamper-resistant formulations are used.
Fentanyl patch exchange
Patients should be asked to return used patches to the pharmacy for more to be dispensed. This is required by law in Ontario.
Promote patch exchange. Discuss medication storage.
Naloxone
Provide naloxone for patients who are identified as at risk for opioid overdose (high dose, medical history/comorbidities).
Recommend and dispense naloxone to patients using opioids with appropriate education and training. Family and friends or others who are likely to witness an overdose should also be provided naloxone. GAD-7, Generalized Anxiety Disorder-7; MED, morphine equivalent daily; NSAID, nonsteroidal anti-inflammatory drug; PHQ-9, Patient Health Questionnaire-9; PTSD, posttraumatic stress disorder; SNRI, serotonin-norepinephrine reuptake inhibitor; SUD, substance use disorder; TCA, tricyclic antidepressant. Guideline recommends them. Instead, potential application of the recommendations must be individualized for patients. Discussion needs to focus on the pros and cons from their perspective and risks tailored specifically to them and their experience. One concept that is often important to clarify is opioid-related hyperalgesia, 10 when opioids cause pro-nociceptive or sensitizing effects. As opioid doses increase, they may actually be increasing pain. This can be very counterintuitive for patients but potentially motivating to decrease opioid doses. Listening to patients is an essential component of providing individualized recommendations.
Framework application
Recall the patient with a prescription for "oxycodone ER 40 mg po BID" (MED = 120 mg). She is 50 years old, with a history of a spinal cord injury several years ago. She developed widespread chronic pain 2 years after her injury, with nociceptive and neuropathic features. She describes her opioids as "taking the edge off her pain" and says that "nothing else works. " Her pain is consistently rated as an average of 7 out of 10 and her functional interference score on the Brief Pain Inventory is high (70 out of a possible score of 90), since she reports that her pain interferes with many domains, including her bOX 4 Talking to patients about the Guideline: Using a motivational approach When providing information, ensure the conversation occurs in a private space. Provide enough time for patients to formulate their thoughts and respond.
Avoid the "Righting Reflex, " which is the urge to jump in and provide advice or correct misinformation perhaps before they are ready to receive it, since: "This is the only thing that gets me through the day. " "You don't know what I am going through. " Taking more opioids than prescribed is dangerous.
"I am so ashamed that I need to take these medications. " "Next time, I'm not going to say anything. " How are the opioids working for you?
"I need to justify why I should stay on opioids. "
Instead, use a structure such as Elicit-Provide-Elicit, with a priority on checking in with the patient before and after providing some information.
elICIT and listen carefully; consider linking together pros and cons (if any). "Tell me about the upsides and downsides you see from your opioids. " "What are your expectations for this opioid trial?" "What are some things that you have been able to do lately that you have really enjoyed?"
PROVIDe individualized benefits and risks to review with patients. "So you have already had a few falls, and you have no energy to do anything. I also see that your testosterone level is low and you were hospitalized for a pneumonia infection last year. " "It seems from your pain diagram you may be experiencing something called opioid-induced hyperalgesia, where the opioids may actually be making your pain worse. " "It sounds like you really wish you could get out and play with your grandkids, but your pain is still really limiting you. " elICIT "We have discussed a lot. What are you most concerned about?" "How does this information fit with what you were already thinking?" "How do you feel now knowing some of this information?"
PRaCtiCe guideLiNes relationships with other people, her ability to do things she enjoys and her sleep. She reports no adverse effects from her use of opioids. Her other medical history is significant for anxiety, neurogenic bladder and bowel, painful pressure ulcers and orthostatic hypotension. Last year, she was diagnosed with depression but is refusing trials of antidepressants and any pain medications besides opioids because of bad reactions in the past. She takes clonazepam 1 mg PO at bedtime for sleep. She has no history of or active substance use disorder. Past trials without success include morphine and nonsteroidal antiinflammatory drugs (NSAIDs), and she did not tolerate amitriptyline or nabilone.
Assessment and Plan:
1. Nonopioid and nonpharmacological therapy is not optimized.
Recommend nonpharmacological strategies (e.g., gentle exercise, relaxation, distraction, others); may refer to another health care provider (e.g., occupational therapist, physical therapist, nurse) for additional strategies. Use a motivational approach to help with behaviour change and elicit her reasons for resistance. Recommend a trial of a gabapentinoid, or initiate it if she is willing.
2. Active psychiatric disorder should be stabilized before opioid therapy.
The patient is already on opioid therapy, but her active depression should still be stabilized. Work with her to consider treatment options for depression, including psychotherapy (e.g., cognitive behavioural therapy), and explore her resistance to pharmacotherapy. If she changes her mind, recommend or initiate a trial of duloxetine to manage her depression and her neuropathic pain.
Dose is above 90 mg MED daily.
The patient is not reporting any adverse effects but is at risk of rare but serious side effects of opioid use disorder, opioid poisoning and opioid-related death and consequences of longterm use, including opioid-related hyperalgesia, opioid-induced hypogonadism and sleep apnea. She should be referred for a sleep study. She is receiving limited benefit from her opioid therapy but is resistant to change. Recommendations to explore with her using a motivational approach include rotation and/or tapering, though ultimately her preferences should guide management.
Coprescribing with benzodiazepine.
She is using clonazepam. Work with her to weigh the benefits she sees with clonazepam for sleep with the increased risk of respiratory depression when taken with an opioid and the potential negative impact on her sleep architecture. Recommend tapering her benzodiazepine. She can provide significant input into the sequence of changes.
Risk of opioid poisoning.
Recommend and dispense a naloxone kit and provide her with appropriate education.
Discussion
This proposed framework for pharmacists does not replace the Guideline but is intended to serve as a tool for pharmacists to identify opportunities for implementation in practice during medication reviews and the development of care plans.
Pharmacists working with patients in all settings have a responsibility to foster opioid stewardship. They are formally recognized in the Guideline for making important contributions to the interprofessional team, including their role in opioid tapering. Currently, pharmacists are limited in their ability to independently prescribe opioids and benzodiazepines due to federal restrictions on the recognition of pharmacists as prescribers in the Controlled Drugs and Substances Act. It is our opinion that pharmacists could help more to meet patient needs if they had the ability to more directly intervene, for example, with respect to tapering and rotation of opioids or tapering of benzodiazepines, especially when coprescribed with opioids.
Several practice tools have previously been developed related to application of the Guideline. Recently, we published a paper in the Canadian Pharmacists Journal with a group of pharmacist coauthors from across Canada, focusing on practical advice for opioid tapering, guided by evidence, and including responses to frequently asked questions. 11 The Alberta College of Pharmacists published their own guidance document for assessment and monitoring of individuals using opioids in 2017. 12 They outlined the responsibilities that pharmacists must accept in the care of patients using opioids, including maintenance of a professional relationship with each individual using opioid medications; thorough assessment, including a review of their electronic health record every time an opioid Practice guidelines is dispensed or sold; detailed documentation of the assessment and written treatment plan; collaboration with prescriber and other health care professionals; and monitoring for signs of opioid misuse, diversion or addiction, with appropriate action if identified. Our framework supplements their document. In addition, the Opioid Manager, a point-of-care tool, is applicable for an interprofessional audience and was updated to provide essential information and advice on application of the 2017 Guideline. 13 Other infographics, decision aids and tools related to opioid conversion calculations are also available, including the Opioid Manager (https:// www.opioidmanager.com/opioid-manager), RxFiles (www.rxfiles.ca/rxfiles) and MAGICapp (https://app.magicapp.org). There is work to be done to identify and inventory these tools and to assess if additional tools are needed to support pharmacists. Our group, the CPhA & Partners Opioid Working Group, plans to work to identify these gaps and address them as needed.
Conclusion
Pharmacists have an important and leading role as opioid stewards to support people who have chronic pain in making rational decisions about opioid therapy and to promote strategies to optimize safety. We propose implementation of the Guideline in practice using our framework of comprehensive assessment and management, grounded by a motivational approach in educating patients about the Guideline, so they can make informed and thoughtful decisions about their opioid therapy. 
